Kiniksa Pharmaceuticals International, plc (KNSA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
105 Piccadilly
London, GL W1J 7NJ
United Kingdom of Great Britain and Northern Ireland (the)
Phone
7814399100
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
366
First IPO Date
May 24, 2018
| Name | Title | Pay | Year Born |
| Sanj K. Patel | Chief Executive Officer & Chairman of the Board | 2.24M | 1969 |
| Mark Ragosa | Executive VP & CFO | 1.08M | 1974 |
| Eben Tessari | Consultant | 1.13M | 1982 |
| John F. Paolini | Executive Vice President & Chief Medical Officer | 1.13M | 1965 |
| Ross Michael Moat | Executive VP, COO & Principal Operating Officer | 1.2M | 1980 |
| Aaron Young | Chief Intellectual Property Officer | 0 | N/A |
| Martina Struck | Senior VP & Chief Regulatory Officer | 0 | N/A |
| Joseph Pirrello | Chief Business Officer | 0 | N/A |
| Michael R. Megna | Senior Vice President & Chief Accounting Officer | 0 | 1971 |
| Jonathan Kirshenbaum | Investor Relations Officer | 0 | N/A |
| Mei Jang | Senior VP & Chief Technical Officer | 0 | N/A |
| Douglas Barry | Senior Vice President, Chief Legal Officer & Secretary | 0 | N/A |
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.